Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study

Dalfampridine extended release tablets (D-ER; prolonged-release fampridine in Europe) are available to improve walking in patients with multiple sclerosis (MS). D-ER is mainly renally eliminated; the approved 10-mg twice daily dose is contraindicated in the United States in patients with moderate or...

Descripción completa

Detalles Bibliográficos
Autores principales: Samara, Emil, Winkle, Peter, Pardo, Patricia, Henney, Herbert R, Way, Susan L, Brown, Eppie, Lee, Angela, Blight, Andrew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263161/
https://www.ncbi.nlm.nih.gov/pubmed/24150835
http://dx.doi.org/10.1002/jcph.189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263161/
https://www.ncbi.nlm.nih.gov/pubmed/24150835
http://dx.doi.org/10.1002/jcph.189

Ejemplares similares